Cargando…

A serum factor with potential as a tumour marker in malignant lymphoma.

Detalles Bibliográficos
Autores principales:	Begent, R. H., Tucker, D. F., Keen, J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1980
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010245/ https://www.ncbi.nlm.nih.gov/pubmed/7387837

Ejemplares similares

Identification of PEG-precipitable serum factor associated with malignant lymphoma as C-reactive protein.
por: Walker, L. C., et al.
Publicado: (1983)

Circulating immune complexes as markers of response to chemotherapy in malignant teratomas and gestational trophoblastic tumours.
por: Begent, R. H., et al.
Publicado: (1982)

Tumour-marker levels and prognosis in malignant teratoma of the testis.
por: Germa-Lluch, J. R., et al.
Publicado: (1980)

Serum metalloproteinases and their inhibitors: markers for malignant potential.
por: Baker, T., et al.
Publicado: (1994)

In vivo uptake of 131I-5-iodo-2-deoxyuridine by malignant tumours in man.
por: Philip, P. A., et al.
Publicado: (1991)

Malignant lymphomas as tumours of the immune system.
por: Berard, C. W., et al.
Publicado: (1980)

Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker
por: Kruseova, Jarmila, et al.
Publicado: (2013)

Serum marker potential of placental alkaline phosphatase-like activity in testicular germ cell tumours evaluated by H17E2 monoclonal antibody assay.
por: Tucker, D. F., et al.
Publicado: (1985)

Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits.
por: Ledermann, J. A., et al.
Publicado: (1988)

Cellular fibronectin in serum and plasma: a potential new tumour marker?
por: Ylätupa, S., et al.
Publicado: (1995)

Expression of Potential Dermal Progenitor Cell Markers in the Tumour and Stroma of Skin Adnexal Malignant and Benign Tumours
por: Quist, Sven R., et al.
Publicado: (2019)

Serum proteins as tumour markers for breast cancer.
por: Mattison, P., et al.
Publicado: (1981)

The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.
por: Pedley, R. B., et al.
Publicado: (1994)

Frequency of serum tumour marker monitoring.
por: Colls, B. M.
Publicado: (1991)

Chemotherapy of advanced malignant teratomas.
por: Newlands, E. S., et al.
Publicado: (1980)

Serum Enzyme Activity During Radiotherapy of Malignant Tumours
por: Holsti, L. R.
Publicado: (1965)

Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.
por: Seckl, M. J., et al.
Publicado: (1990)

Neuron-specific enolase--a serum tumour marker in seminoma?
por: Fosså, S. D., et al.
Publicado: (1992)

Correlation between serum albumin and serum zinc in malignant lymphoma
por: Morisaku, Misaki, et al.
Publicado: (2022)

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
por: Casey, J. L., et al.
Publicado: (1996)

Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma
por: Woitge, H W, et al.
Publicado: (2001)

Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab́ fragments
por: Casey, J L, et al.
Publicado: (1999)

The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapy.
por: Crawford, S. M., et al.
Publicado: (1989)

Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma
por: Martynchyk, Arina, et al.
Publicado: (2023)

Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor
por: Yoo, Changhoon, et al.
Publicado: (2014)

Bone disease in testicular and extragonadal germ cell tumours.
por: Hitchins, R. N., et al.
Publicado: (1988)

Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.
por: Marshall, D., et al.
Publicado: (1996)

Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy.
por: Sproston, A. R., et al.
Publicado: (1995)

A marker for hypoxic cells in tumours with potential clinical applicability.
por: Chapman, J. D., et al.
Publicado: (1981)

The geographical distribution of Burkitt's tumour compared with the geographical distribution of other types of malignant lymphoma in Uganda.
por: Wright, D. H., et al.
Publicado: (1966)

Comparison of four serum tumour markers in the diagnosis of colorectal carcinoma.
por: van der Schouw, Y. T., et al.
Publicado: (1992)

Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
por: Haglund, C., et al.
Publicado: (1986)

Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
por: Rehn, S., et al.
Publicado: (1995)

Doppler assessment of the uterine circulation and the clinical behaviour of gestational trophoblastic tumours requiring chemotherapy.
por: Long, M. G., et al.
Publicado: (1992)

HOX transcription factors are potential targets and markers in malignant mesothelioma
por: Morgan, Richard, et al.
Publicado: (2016)

Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.
por: Marshall, D., et al.
Publicado: (1995)

Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiple myeloma.
por: Rømer, F. K., et al.
Publicado: (1980)

The Potential Malignancy of a Solitary Fibrous Tumour of the Lung
por: Shukla, Rajeev, et al.
Publicado: (2015)

Serum Immunoglobulins as Diagnostic Markers in Smokeless Tobacco Users for Prevention of Oral Potentially Malignant Disorders
por: Shukla, Anjani Kumar, et al.
Publicado: (2020)

The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.
por: Gronowitz, J. S., et al.
Publicado: (1983)

Cannot write session to /tmp/vufind_sessions/sess_0n2gnolt98ivk8285bmokea5d8